Agios's mitapivat data in sickle cell disappoints at ASH presentation

• An update on Agios Pharmaceuticals’ (AGIO -15.3%) experimental sickle cell disease medicine, mitapivat, has potentially missed some investors’ expectations after it was shown that six of 11 patients hit a key benchmark to show improvement of their disease in Phase 1 study. Data